drugset
drugset / Trial / NCT06662773

Drug-Drug Interaction (DDI) Study for TQB3616

NCT06662773 ↗

Phase 1 Not yet recruiting 40 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the effect of itraconazole/rifampicin on the pharmacokinetics of TQB3616 capsules. To assess the safety of a single dose of oral TQB3616 capsules and in combination with itraconazole/rifampicin.

Timeline

Start
2024-11
Primary completion
2025-03
Completion
2025-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject Rifampin Small molecule 600 mg Oral
Subject TQB3616 Small molecule 60 mg Oral
Subject TQB3616 Small molecule 180 mg Oral

Indications

No indication recorded.